Plecanatide vs PACAP-38
Head-to-head comparison of Plecanatide (Plecanatide) and PACAP-38 (Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38)) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | PACAP-38 |
|---|---|---|
| Category | Gastrointestinal | Cognitive Enhancement |
| Full Name | Plecanatide | Pituitary Adenylate Cyclase-Activating Polypeptide-38 (human PACAP-38) |
| Molecular Weight | Approx. 1620 Da | 4534 Da |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | minutes |
| Amino Acids | 16 | 38 aa |
| Typical Dose | 3 mg once daily | 10-100 µg preclinical range |
| Route | Oral | Intranasal |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 650 |
| Research Status | Clinical | Pre-clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
PACAP-38 Benefits
- ✓synaptic plasticity
- ✓BDNF upregulation
- ✓neuroprotection
- ✓memory consolidation
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
PACAP-38 Dosing
0.1-1 nmol ICV in rodents|10-100 µg intranasal in preclinical studies|single-dose or short repeated protocols
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
PACAP-38 Side Effects
- ⚠headache-like effects
- ⚠flushing
- ⚠hypotension
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
PACAP-38
PACAP-38 is one of the most studied endogenous neuropeptides for protecting neurons from ischemic and excitotoxic damage. Preclinical literature also links it to hippocampal plasticity and learning-related signaling, including increased BDNF expression.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.